Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026)
Perspective Therapeutics (CATX) reported Change in Receivables of $52000.0 for Q1 2026, up 236.84% on a YoY basis from $15437.5 in Q1 2025, and up 130.06% sequentially from -$173000.0 in Q4 2025.
Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 17 years of Change in Receivables data on file, last reported at $52000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 236.84% year-over-year to $52000.0; the trailing twelve-month figure through Mar 2026 stood at -$20000.0 (up 97.83% YoY), and the FY2025 full-year result was -$110000.0, up 89.51% from the prior year.
- Change in Receivables improved to $52000.0 in Q1 2026, from -$173000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $618000.0 in Q3 2023 to a low of -$813000.0 in Q2 2024.
- A 5-year average of -$90000.0 and a median of -$46000.0 in 2025 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables soared 242.4% in 2023 and tumbled 16700.0% in 2024, its largest moves.
- Tracing CATX's Change in Receivables over 5 years: stood at -$245000.0 in 2022, then plunged by 131.02% to -$566000.0 in 2023, then surged by 61.66% to -$217000.0 in 2024, then increased by 20.28% to -$173000.0 in 2025, then soared by 130.06% to $52000.0 in 2026.
- Business Quant data shows CATX's Change in Receivables at $52000.0 in Q1 2026, -$173000.0 in Q4 2025, and -$46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 287.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -124.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 52,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -566,000.00 |
| Dec 31, 2023 | -566,000.00 |